Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors
OBJECTIVES:
- To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by
immunohistochemistry in primary tumors.
- To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by
immunohistochemistry in primary tumors.
- To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM
expression.
- To determine if BRM promoter polymorphisms correlate with loss of BRM expression in
primary rhabdoid tumors.
- To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons
in genomic DNA derived from frozen samples.
OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2
expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.
Observational
N/A
Absence or presence BRG1 and BRM expression in rhabdoid tumors
No
David Reisman, MD, PhD
Principal Investigator
University of Florida
United States: Federal Government
CDR0000728521
NCT01553175
March 2012
Name | Location |
---|